Abstract
Clinical aspects and pathology of pulmonary hypertension (PH) in patients with systemic lupus erythematosus (SLE) have been reported to be similar to those in patients with idiopathic pulmonary arterial hypertension (IPAH). To determine whether PH in these patients is similar, we compared the clinical characteristics, hemodynamics at diagnosis, and survival in groups of patients with SLE–PH and IPAH. We reviewed the case records of 20 patients with SLE–PH and 34 patients with IPAH, who had been assessed by echocardiography or right cardiac catheterization at Asan Medical Center, Seoul, Korea, from January 1995 to October 2003. Clinical features, laboratory data, chest X-rays, electrocardiogram results, pulmonary function tests, pulmonary perfusion scans, echocardiographic findings, serologic profiles, and survival were compared in the two groups of patients. The mean follow-up period was 18.1±20.6 months for patients with SLE–PH and 33.0±23.4 months for patients with IPAH. During follow-up, 12 SLE–PH (60%) and 11 IPAH (32%) patients died. For SLE–PH, the 3-year survival rate was 44.9% and the 5-year survival rate was 16.8%. For IPAH, the 3-year survival rate was 73.4% and the 5-year survival rate was 68.2% (p=0.02). There were no other significant differences in clinical characteristics and laboratory data between the two groups. In contrast to previous reports that the prognosis of patients with pulmonary arterial hypertension associated with collagen vascular disease was better than that of patients with IPAH, we found that the prognosis of patients with SLE–PH was much worse than that of patients with IPAH.
Similar content being viewed by others
References
Perez HD, Kramer N (1981) Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 11:177–181
Quismorio FP Jr, Sharma O, Koss M, Boylen T, Edmiston AW, Thornton PJ, Tatter D (1984) Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13:349–359
Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB (1995) Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 129:510–515
Pan TL, Thumboo J, Boey ML (2000) Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 9:338–342
Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287
Asherson RA, Hackett D, Gharavi AE, Harris EN, Kennedy HG, Hughes GR (1986) Pulmonary hypertension in systemic lupus erythematosus: a report of three cases. J Rheumatol 13:416–420
Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR (1990) Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 17:1292–1298
Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY (1999) Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 17:539–545
British Cardiac Society Guidelines and Medical Practice Committee (2001) Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86(Suppl 1):I1–I13
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216–223
Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, Ito K (1997) Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest 111:36–43
Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12S
Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265–270
Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M (1998) Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 32:1068–1073
Orens JB, Martinez FJ, Lynch JP 3rd (1994) Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 20:159–193
Simonson JS, Schiller NB, Petri M, Hellmann DB (1989) Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 16:918–925
Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929
Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243
Pines A, Kaplinsky N, Goldhammer E, Olchovsky D, Frankl O (1982) Corticosteroid responsive pulmonary hypertension in systemic lupus erythematosus. Clin Rheumatol 1:301–304
Morelli S, Giordano M, De Marzio P, Priori R, Sgreccia A, Valesini G (1993) Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 2:367–369
Groen H, Bootsma H, Postma DS, Kallenberg CG (1993) Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 20:1055–1057
Sanchez O, Humbert M, Sitbon O, Simonneau G (1999) Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 54:273–277
Gonzalez-Lopez L, Cardona-Munoz EG, Celis A, Garcia-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, Garcia-Gonzalez C, Garcia-Gonzalez A, Sanchez-Ortiz A, Trujillo-Hernandez B, Gamez-Nava JI (2004) Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 13:105–112
Padmakumar K, Singh RR, Rai R, Malaviya AN, Saraya AK (1990) Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations. Ann Rheum Dis 49:986–989
Martinuzzo ME, Pombo G, Forastiero RR, Cerrato GS, Colorio CC, Carreras LO (1998) Lupus anticoagulant, high levels of anticardiolipin, and anti-beta2-glycoprotein I antibodies are associated with chronic thromboembolic pulmonary hypertension. J Rheumatol 25:1313–1319
Colorio CC, Martinuzzo ME, Forastiero RR, Pombo G, Adamczuk Y, Carreras LO (2001) Thrombophilic factors in chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 12:427–432
Buchanan RR, Wardlaw JR, Riglar AG, Littlejohn GO, Miller MH (1989) Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheumatol 16:757–761
Mayumi T, Nagasawa K, Inoguchi T, Yamauchi Y, Ishii Y, Tada Y, Umeda F, Niho Y (1991) Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant. Ann Rheum Dis 50:543–547
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party on systemic lupus erythematosus. Medicine (Baltimore) 72:113–124
Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH (1986) Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 8:1307–1311
Yousem SA (1990) The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21:467–474
Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:1628–1631
Ohar J, Polatty C, Robichaud A, Fowler A, Vetrovec G, Glauser F (1985) The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension. Chest 88:263S–265S
Chaouat A, Weitzenblum E, Higenbottam T (1996) The role of thrombosis in severe pulmonary hypertension. Eur Respir J 9:356–363
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903
Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121:409–415
Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, Brundage BH (1997) Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30:343–349
McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338:273–277
Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE (2000) Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 117:14–18
Horn EM, Barst RJ, Poon M (2000) Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 118:1229–1230
Gomez-Sanchez MA, de la Calzada CS, Gomez Pajuelo C, Tascon JC, Alonso M, Andreu J, Aranzana M, de la Fuente A (1991) Different hemodynamic responses between acute and chronic infusion of iloprost (prostacyclin-stable analogue) in severe pulmonary hypertension. Am Rev Respir Dis 144:1404–1405
Mok MY, Tse HF, Lau CS (1999) Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Lupus 8:328–331
Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long–term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342:1866–1870
Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N (1996) Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 78:244–247
Ooiwa H, Miyazawa T, Yamanishi Y, Hiyama K, Ishioka S, Yamakido M (2000) Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue. Intern Med 39:320–323
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chung, SM., Lee, CK., Lee, E.Y. et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25, 866–872 (2006). https://doi.org/10.1007/s10067-006-0206-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0206-5